Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Merck Sharp & Dohme LLC
Modality
UNKNOWN
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03740178CT.gov Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005) | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cognitive Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| mk-4334 (this asset) | Merck Sharp & Dohme LLC | P1 | C · 39 |
| Nicotine | University of Southern California | P2 | BBB |
| Oxybutynin | University of Alberta | P4 | BBB |
| Levodopa | Vanderbilt University Medical Center | P4 | BB |
| Rivastigmine | VA Office of Research and Development | P4 | BB |
| Metformin | Fudan University | P4 | BB |
| Memantine | UNC Lineberger Comprehensive Cancer Center | P3 | BB |
| Egb 761® | Ipsen | P4 | BB |
| Ginkgo Biloba | Dr. Willmar Schwabe GmbH & Co. KG | P4 | BB |
+42 more in the Cognitive Disorder cohort
Other indications for mk-4334
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Schizophrenia | — | P1 | CC · 47 |
| Alzheimer Disease | — | P1 | C · 39 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. mk-4334 in Cognitive Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/mk-4334-cognitive-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →